En Carta Diagnostics vs Respiro Diagnostics
En Carta Diagnostics vs Respiro Diagnostics, compared side by side on 13 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: En Carta Diagnostics is on 52/100 and Respiro Diagnostics on 39/100.
Where each one leads
En Carta Diagnostics
- our overall score: 52/100 against 39/100
- funding raised: $5.0M against $1.0M
Respiro Diagnostics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | En Carta Diagnostics | Respiro Diagnostics |
|---|---|---|
| What it is | Developing a new generation of molecular diagnostics for at-home use, combining laboratory accuracy with rapid test simplicity. | Developing breath-based diagnostics for lung diseases. |
| Category | Biotechnology, HealthTech, Diagnostics, Medical Devices | Biotechnology, Healthcare, Diagnostics, Medical Devices |
| Sells toBusiness model | B2B2C | B2B |
| Offering | Hardware | Platform |
| Founded | 2022 | Not published |
| Headquarters | Paris, France | Cambridge, United Kingdom |
| Status | Inactive | Active |
Size, funding and growth
| Measure | En Carta Diagnostics | Respiro Diagnostics |
|---|---|---|
| Employees | 12 | Not published |
| Total funding | $5.0M | $1.0M |
| Latest round | Seed | Pre-Seed |
| LinkedIn followers | 2,091 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | En Carta Diagnostics | Respiro Diagnostics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 52/100 | 39/100 |
| Traction | 45/100 | 30/100 |
| Team | 70/100 | 30/100 |
| Search visibility | 20/100 | 25/100 |
| Quality | 58/100 | 48/100 |
| Domain ratingLink authority, 0-100 | 0/100 | Not published |
En Carta Diagnostics vs Respiro Diagnostics: common questions
Which is better, En Carta Diagnostics or Respiro Diagnostics?
On our 0-100 score En Carta Diagnostics rates higher (52/100 against 39/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 13 data points above: read the rows that match what you are buying for.
How do En Carta Diagnostics and Respiro Diagnostics compare on the numbers?
En Carta Diagnostics leads on our overall score (52/100 against 39/100), funding raised ($5.0M against $1.0M).
Read the full En Carta Diagnostics review and pricing or the Respiro Diagnostics review and pricing. You can also browse other En Carta Diagnostics alternatives we track.